DESIGN AND FORMULATION OF NEXT GENERATION DRY POWDER INHALERS: OPPORTUNITIES AND CHALLENGES

Krishna Narasimh Midde

Midde Krishna Narasimh Priyadarshini Institute of Pharmaceutical Education and Research, 5th Mile, Pulladigunta, Guntur-522017, Andhra Pradesh, India.

Abstract

Dry powder inhalers (DPIs) have become a significant system for pulmonary drug delivery, attributed to their breath-actuated mechanism, portability, and stability of formulation. In recent decades, notable progress in DPI technology has tackled major challenges related to inadequate powder flow, variability in dosing, and inhalation performance that depends on the patient. The development of advanced DPIs emphasizes innovative particle engineering techniques such as spray drying, supercritical fluid technology, and formulations without carriers to improve aerosolization efficiency and deep lung deposition. The incorporation of new excipients, techniques for surface modification, and engineered porous particles has further enhanced the dispersibility of powders and consistency in dosing. Additionally, innovations in devices, including low-resistance inhalers, active dispersion mechanisms, and smart inhalers with digital sensors, are revolutionizing patient adherence and therapeutic monitoring. Future advancements in DPIs are anticipated to focus on personalized medicine, integrating patient-specific inhalation profiles and connectivity with digital health platforms. Furthermore, the expanding use of DPIs for systemic delivery, vaccines, biologics, and gene therapies underscores their increasing clinical importance beyond just respiratory conditions. Despite these advancements, challenges such as scalability in manufacturing, regulatory demands, and long-term stability persist. Ongoing interdisciplinary research that merges formulation science, device engineering, and clinical assessment will be vital in progressing the next generation of dry powder inhalers to achieve better therapeutic results.

Keywords: Dry powders inhalers, nasal drug delivery, long term stability, therapeutic action

Downloads

Download data is not yet available.

References

1. Lee SH, Yap WX, Jiang CQ, Ler WX, Teo JW, Ng SK, Heng D. Designing a “ready-to-use” powder formulation platform for inhaled protein therapeu-tics. J Drug Deliv Sci Technol. 2022 Oct;76:103820. https://doi.org/10.1016/j.jddst.2022.103820
2. Wilson EM, Luft CJ, DeSimone JM. Formulation of high-performance dry powder aerosols for pulmo-nary protein delivery. Pharm Res. 2018 Oct;35(10):195. https://doi.org/10.3390/pharmaceutics12111025
3. Plaza V, Calle M, Molina J, Quirce S, Sanchis J, Viejo JL, et al. External validation of recommenda-tions of multidisciplinary consensus about inhaled therapies. Arch Bronconeumol. 2012 Jun;48(6):189–96. https://doi.org/10.1016/j.arbr.2012.03.007
4. Berkenfeld K, Lamprecht A, McConville JT. Devices for dry powder drug delivery to the lung. AAPS PharmSciTech. 2015 Jun;16(3):479–90. https://doi.org/10.1208/s12249-015-0317-x
5. Telko MJ, Hickey AJ. Dry powder inhaler formula-tion. Respir Care. 2005 Sep;50(9):1209–27. https://doi.org/10.1089/jamp.2023.29104.ajh
6. Mohan AR, Wang Q, Dhapare S, Bielski E, Kavi-ratna A, Han L, et al. Advancements in the design and development of dry powder inhalers and po-tential implications for generic development. Phar-maceutics. 2022 Nov;14(11):2495. https://doi.org/10.3390/pharmaceutics17110096
7. Lavorini F, Pistolesi M, Usmani OS. Recent ad-vances in capsule-based dry powder inhaler tech-nology. Multidiscip Respir Med. 2017 May;12(1):11. https://doi.org/10.3390/pharmaceutics13111936
8. Onoue S, Aoki Y, Matsui T, Kojo Y, Misaka S, Mi-zumoto T, et al. Formulation design and in vivo evaluation of dry powder inhalation system of VIP derivative in experimental asthma/COPD model rats. Int J Pharm. 2011 May;410(1–2):54–60. https://doi.org/10.1016/j.ijpharm.2011.03.021
9. Okuda T, Morishita M, Mizutani K, Shibayama A, Okazaki M, Okamoto H. Development of spray-freeze-dried siRNA/PEI powder for inhalation. J Control Release. 2018 Jun;279:99–113. https://doi.org/10.1016/j.jconrel.2018.04.XXX
10. Wauthoz N, Hennia I, Ecenarro S, Amighi K. Im-pact of capsule type on aerodynamic performance of inhalation products. Int J Pharm. 2018 Dec;553(1–2):47–56. https://doi.org/10.1016/j.ijpharm.2018.10.034
11. Flume PA, Amelina E, Daines CL, Charlton B, Leadbetter J, Guasconi A, et al. Efficacy and safety of inhaled dry-powder mannitol in cystic fibrosis. J Cyst Fibros. 2021 Nov;20(6):1003–9. https://doi.org/10.1016/j.jcf.2021.02.011
12. Alagusundaram M, Deepthi N, Ramkanth S, et al. Dry powder inhalers—an overview. Int J Res Pharm Sci. 2010;1(1):34–42. https://doi.org/10.1016/j.ejps.2018.03.004
13. Daniher DI, Zhu J. Dry powder platform for pul-monary drug delivery. Particuology. 2008 Aug;6(4):225–38. https://doi.org/10.1016/j.ejps.2018.03.004
14. Alagusundaram M, Deepthi N, Ramkanth S, et al. Dry powder inhalers—an overview. Int J Res Pharm Sci. 2010;1(1):34–42. https://doi.org/10.1016/j.ejps.2018.03.004
15. Chan HK. Dry powder aerosol delivery systems: current and future research directions. J Aerosol Med. 2006 Mar;19(1):21–7. https://doi.org/10.1089/jam.2006.19.21
16. Asif DF, Munir H, Ghafoor S, Abrar M, Nawaz MN, Ahsan A. Dry powder inhaler devices. J Cell Sci Ther. 2017;8:271. https://doi.org/10.22270/ajprd.v11i3.1268
17. Price R, Farias G, Ganley W, Shur J. Challenging bioequivalence hurdles for OINDPs. In: Respiratory Drug Delivery Asia 2018. 2018. p. 1–14. https://doi.org/10.1089/jamp.2009.0803
18. Lee SH, Heng D, Xavier VJ, Chan KP, Ng WK, Zhao Y, et al. Inhaled nonsteroidal polyphenolic al-ternatives for anti-inflammatory therapy. Powder Technol. 2018 Nov;339:244–55. https://doi.org/10.1016/j.powtec.2018.08.005
19. U.S. Food and Drug Administration (FDA). Formal meetings between FDA and ANDA applicants of complex products under GDUFA. Guidance for Industry. 2017. https://doi.org/10.1093/jlb/lsy002
20. Xiroudaki S, Schoubben A, Giovagnoli S, Rekkas DM. Dry powder inhalers in the digitalization era. Pharmaceutics. 2021 Sep;13(9):1455. https://doi.org/10.3390/pharmaceutics13091455
21. Leiner S, Parkins D, Lastow O. Inhalation devices and patient interface: human factors. AAPS J. 2015 Mar;17(2):457–61. https://doi.org/10.1208/s12248-015-9717-9
22. Rahimpour Y, Kouhsoltani M, Hamishehkar H. Alternative carriers in dry powder inhaler formula-tions. Drug Discov Today. 2014 May;19(5):618–26. https://doi.org/10.1016/j.drudis.2013.11.013
23. Markovic I. Evaluation of safety and quality impact of extractables and leachables. Expert Opin Drug Saf. 2007 Sep;6(5):487–91. https://doi.org/10.1517/14740338.6.5.487
24. Liang W, Chow MY, Lau PN, et al. Inhalable dry powder formulations of siRNA. Mol Pharm. 2015 Mar;12(3):910–21. https://doi.org/10.1021/mp500745v
25. Nama S, Chandu B, et al. Development and valida-tion of RP-HPLC method for aprepitant. Trop J Pharm Res. 2011;10(4). https://www.ajol.info/index.php/tjpr/article/view/69565
26. Rani CHU, Sumalatha G, Rao CHB, Varalakshmi TN. Alzheimer’s disease—pharmacotherapeutic in-terventions. Int J Pharm Chem Sci. 2013;2(2). https://ijpcsonline.com/archives6/
27. Prasanthi G, Chandu B, et al. Chemical pharmacol-ogy of khat leaves. J Glob Trends Pharm Sci. 2014;5(4):2024–9. https://www.jgtps.com/admin/uploads/mw7QGy.pdf
28. Nama S, Chandu B, et al. Development and valida-tion of RP-HPLC method for aprepitant. Trop J Pharm Res. 2011;10(4).
29. Hwisa NT, Gindi S, Rao CB, Katakam P, Rao Chandu B. Evaluation of antiulcer activity of Picrasma quassioides. Vedic Res Int Phytomedicine. 2013;1:27. https://www.researchgate.net/publication/248995990
30. Gindi S, Methra T, Chandu R, et al. Antiurolithiatic and antioxidant activity of Ageratum conyzoides. World J Pharm Pharm Sci. 2013;2(2):636–49. https://www.researchgate.net/profile/Revathi-Boyina/publication/251566463